抗糖蛋白IIbIIIa抗体诱导的原发性免疫性血小板减少症中血小板去唾液酸化的临床证据
基于维也纳ITP生物样本库,评估133例成人原发性ITP患者血清诱导血小板去唾液酸化的能力及其临床关联。29%患者血清可诱导去唾液酸化,该能力与血小板结合抗糖蛋白IIbIIIa抗体、血小板生成素>50 pg/mL及更高出血评分相关,多因素分析仅抗血小板抗体阳性保持独立关联。
要点
- 29%的原发性ITP患者血清可诱导血小板去唾液酸化。
- 去唾液酸化能力与血小板结合抗糖蛋白IIbIIIa抗体、血小板生成素>50 pg/mL及更高出血评分相关。
- 多因素分析中仅抗血小板抗体阳性与去唾液酸化能力独立相关。
核心结论
- 约三分之一原发性ITP患者存在血小板去唾液酸化能力,且与血小板结合抗糖蛋白IIbIIIa抗体相关,但需更多研究确立与抗糖蛋白Ib-IX抗体的联系。
- 去唾液酸化能力与更严重的出血表型相关,但与血小板计数、疾病病程、ITP治疗及脾切除难治性的关联未获证实,与既往数据不同。
研究设计与样本
- 研究基于维也纳ITP生物样本库(EC 1843/2016),纳入133例成人原发性ITP患者,其中28%为新诊断、72%为持续性/慢性。
- 采用凝集素结合试验评估血小板表面β-半乳糖和N-乙酰葡糖胺暴露以判定去唾液酸化。
主要发现
- 133例患者中38例(29%)血清可诱导血小板去唾液酸化。
- 去唾液酸化组较无去唾液酸化组更常见血小板结合自身抗体(19/46,50% vs 27/95,28.4%;P=0.018)。
- 去唾液酸化组较无去唾液酸化组更常见血小板生成素>50 pg/mL(23/34,67.6% vs 37/38,42.0%;P=0.011)。
- 去唾液酸化组出血评分中位数3.0(IQR 1.0-5.0) vs 无去唾液酸化组1.0(IQR 0.0-4.0);P=0.043。
- 多因素二元logistic回归分析中,仅抗血小板自身抗体阳性与去唾液酸化自身抗体保持显著关联。
关键数值与推荐
- 去唾液酸化判定采用凝集素结合试验评估β-半乳糖和N-乙酰葡糖胺暴露。
- 出血评分中位数3.0(IQR 1.0-5.0) vs 1.0(IQR 0.0-4.0),P=0.043。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需更多研究确立去唾液酸化与抗糖蛋白Ib-IX抗体的联系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autoantibody (AAb)-induced platelet desialylation, resulting in increased hepatic platelet clearance, has previously been reported as pathomechanism in immune thrombocytopenia (ITP). OBJECTIVES: To elucidate platelet desialylation capacity and its impact on clinical outcomes in adult primary ITP patients from the Vienna ITP biobank (EC 1843/2016). METHODS: Desialylation was assessed using a lectin-binding assay which evaluated the exposure of β-galactose and N-acetylglucosamine on platelets. RESULTS: Sera from 133 ITP patients (28% newly diagnosed and 72% persistent/chronic) were investigated, where sera of 38 patients (29%) induced platelet desialylation. Patients with desialylation capacity compared with those without more commonly had platelet-bound AAbs (n = 19/46, 50% vs n = 27/95, 28.4%; P = .018), thrombopoietin levels > 50 pg/mL (n = 23/34, 67.6% vs n = 37/38, 42.0%; P = .011), and higher bleeding scores (median [IQR], 3.0 [1.0-5.0] vs 1.0 [0.0-4.0]; P = .043). While the bleeding score overall, specifically the skin bleeding score, thrombopoietin > 50 pg/mL, and the presence of AAbs showed a significant association in univariate analysis with desialylating AAbs, only positivity for antiplatelet AAbs remained significantly associated in multivariate binary logistic regression analysis. In contrast, no association was seen between platelet desialylation capacity and disease duration, ITP treatment, or previous splenectomy. CONCLUSION: Platelet desialylation capacity was seen in a third of primary ITP patients and was associated with platelet-bound antiglycoprotein IIbIIIa AAbs, although more studies are required to establish the linkage with antiglycoprotein Ib-IX AAbs. Desialylation capacity was associated with a more severe bleeding phenotype, while, in contrast to previous data, an association with platelet counts, disease duration, ITP treatment, and splenectomy refractoriness was not confirmed.
引用
- Schramm T, Zlamal J, Rast J, et al. Clinical evidence for antiglycoprotein IIbIIIa antibody-induced platelet desialylation in primary immune thrombocytopenia. J Thromb Haemost. 2025. PMID: 40472900. doi:10.1016/j.jtha.2025.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。